Business Standard

Friday, December 20, 2024 | 04:48 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Flush with cash, Pfizer buys Global Blood Therapeutics in $5.4-bn deal

Pfizer has been on the lookout for acquisitions that could bring in billions in annual sales by the end of the decade

Pfizer
Premium

A person walks past a Pfizer logo amid the coronavirus disease pandemic in the Manhattan borough of New York City (Photo: Reuters)

Reuters
Pfizer Inc on Monday agreed to pay $5.4 billion in cash for sickle cell disease drugmaker Global Blood Therapeutics, as it looks to capitalize on a surge in revenue from its COVID-19 vaccine and treatment.

Pfizer will pay $68.50 per GBT share, which represents a 7.3% premium to its Friday closing price. The deal is at a more than 40% premium where GBT was trading before the Wall Street Journal reported that Pfizer was in advanced talks to buy it on Thursday.

Pfizer's 2021 revenue of $81.3 billion was nearly double the mark from the previous year, due to COVID-19 vaccine sales.

Disclaimer: No Business Standard Journalist was involved in creation of this content

Topics : Pfizer

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in